Direct Plan · IDCW · Sectoral / Thematic · Scheme code 143784
NAV₹31.6120as on 25 Sep 2026
Fund houseMirae Asset Mutual Fund
CategorySectoral / Thematic
Plan & optionDirect · IDCW
History8.2 years
Returns (%)
1M
3M
6M
1Y
3Y
5Y
7Y
10Y
Launch
This scheme
0.07
8.92
18.66
7.77
12.14
4.04
16.61
—
14.70
Nifty 500 benchmark
0.87
4.31
2.15
5.20
12.49
11.41
—
—
15.49
Sectoral / Thematic category median
—
—
—
3.52
14.67
11.99
—
14.72
—
Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
17.1%
0.33
0.44
0.65
5.67%
-36.0%
33.73
Nifty 500 benchmark
17.2%
0.35
0.47
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
83 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
355
-30.9%
10.2%
87.9%
31%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
87%
56%
0.58
17.6%
0.15
17.26
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 83 months this scheme and
Nifty 500 share.
Mirae Asset Healthcare Fund
Direct Plan · IDCW
Allocation
By asset
Equity
99.67%
Cash & Equivalents
0.32%
Mutual Fund Units
0.01%
By market cap
Concentration
Number of stocks
30
Top 5 stocks
39.02%
Top 10 stocks
58.59%
Top 20 stocks
87.45%
Lines in the filing
32
Largest holding
10.90%
Largest sector
Pharmaceuticals & Biotechnology 75.40%
Effective stocks
19.5
Sectors held
5
Cash
0.32%
Effective stocks is what the concentration works out to: a fund holding
30 names but most of its money in a few
behaves like a fund of 20. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
75.40%
Healthcare Services
21.74%
Healthcare Equipment & Supplies
1.44%
Chemicals & Petrochemicals
1.09%
Cash & Equivalents
0.32%
Unclassified
0.01%
Mirae Asset Healthcare Fund
Direct Plan · IDCW · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
1,952,104
387
10.90%
2
Divi's Laboratories Ltd.
Pharmaceuticals & Biotechnology
372,182
352
9.91%
3
Torrent Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
495,204
251
7.06%
4
Apollo Hospitals Enterprise Ltd.
Healthcare Services
236,246
210
5.91%
5
Laurus Labs Ltd.
Pharmaceuticals & Biotechnology
972,748
186
5.24%
6
Glenmark Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
715,107
177
4.99%
7
Dr. Reddy's Laboratories Ltd.
Pharmaceuticals & Biotechnology
1,214,602
140
3.94%
8
Aurobindo Pharma Ltd.
Pharmaceuticals & Biotechnology
789,355
136
3.81%
9
IPCA Laboratories Ltd.
Pharmaceuticals & Biotechnology
617,350
122
3.43%
10
Fortis Healthcare Ltd.
Healthcare Services
1,333,084
121
3.40%
11
Alkem Laboratories Ltd.
Pharmaceuticals & Biotechnology
225,895
120
3.39%
12
Sai Life Sciences Ltd.
Pharmaceuticals & Biotechnology
804,329
117
3.30%
13
Krishna Institute of Medical Sciences Ltd.
Healthcare Services
1,486,653
112
3.16%
14
Aster DM Quality Care Ltd.
Healthcare Services
1,414,393
107
3.01%
15
Onesource Specialty Pharma Ltd.
Pharmaceuticals & Biotechnology
691,867
105
2.96%
16
Dr. Lal Path labs Ltd.
Healthcare Services
508,489
98
2.77%
17
Cipla Ltd.
Pharmaceuticals & Biotechnology
683,610
96
2.71%
18
Max Healthcare Institute Ltd.
Healthcare Services
881,477
92
2.58%
19
Eris Lifesciences Ltd.
Pharmaceuticals & Biotechnology
699,590
91
2.55%
20
Gland Pharma Ltd.
Pharmaceuticals & Biotechnology
300,180
87
2.44%
21
Lupin Ltd.
Pharmaceuticals & Biotechnology
390,170
85
2.40%
22
Biocon Ltd.
Pharmaceuticals & Biotechnology
1,841,719
76
2.13%
23
Mankind Pharma Ltd.
Pharmaceuticals & Biotechnology
312,941
76
2.13%
24
Molbio Diagnostics Ltd.
Healthcare Equipment & Supplies
472,842
51
1.44%
25
Anthem Biosciences Ltd.
Pharmaceuticals & Biotechnology
447,952
40
1.13%
26
Symbiotec Pharmalab Ltd A
Pharmaceuticals & Biotechnology
354,270
35
0.98%
27
Narayana Hrudayalaya Ltd.
Healthcare Services
170,026
32
0.91%
28
Neogen Chemicals Ltd.
Chemicals & Petrochemicals
102,961
23
0.64%
29
Deepak Nitrite Ltd.
Chemicals & Petrochemicals
91,539
16
0.45%
30
TREPS
Unclassified
—
16
0.44%
Mirae Asset Healthcare Fund
Direct Plan · IDCW · where the money sits
What the manager did last month
Between the filings of 31 Jul 2026 and 31 Aug 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹71 cr
₹81 cr
2
0
+2.51%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
Molbio Diagnostics Ltd.
472,842
entered
—
51.4
Symbiotec Pharmalab Ltd A
354,270
entered
—
35.0
Added to
Dr. Reddy's Laboratories Ltd.
176,500
+17.0%
+0.6%
20.4
Sun Pharmaceutical Industries Ltd.
40,000
+2.1%
-0.3%
7.9
Aster DM Quality Care Ltd.
100,000
+7.6%
-8.1%
7.6
Apollo Hospitals Enterprise Ltd.
7,950
+3.5%
-0.7%
7.1
Alkem Laboratories Ltd.
13,000
+6.1%
-7.3%
6.9
Mankind Pharma Ltd.
28,500
+10.0%
-2.0%
6.9
Biocon Ltd.
162,000
+9.6%
-3.2%
6.7
Fortis Healthcare Ltd.
40,000
+3.1%
-4.0%
3.6
Trimmed
Glenmark Pharmaceuticals Ltd.
136,598
-16.0%
+11.0%
33.9
Lupin Ltd.
76,000
-16.3%
-9.4%
16.6
Aurobindo Pharma Ltd.
43,853
-5.3%
+8.7%
7.5
Narayana Hrudayalaya Ltd.
31,662
-15.7%
-6.0%
6.0
Sai Life Sciences Ltd.
25,000
-3.0%
+11.0%
3.7
Anthem Biosciences Ltd.
40,000
-8.2%
+10.4%
3.6
Torrent Pharmaceuticals Ltd.
7,000
-1.4%
-1.1%
3.6
Cipla Ltd.
25,000
-3.5%
-4.3%
3.5
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹775,449
₹175,449
10.20%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 28 Sep 2026.
